



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

28 Jun 2021 (#19)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

[NOT-AI-21-057](#) Notice of Special Interest (NOSI)—HIV/AIDS in the Era of COVID-19 - When Pandemics Collide. The purpose of this Notice of Special Interest (NOSI) is to communicate special interest in epidemiology investigations to quantify the impact of the coronavirus disease 2019 (COVID-19) pandemic on Human Immunodeficiency Virus (HIV) prevention, incidence, transmission, and outcomes. This NOSI encourages research on the impact and strategies needed to adapt the HIV/AIDS response through agile and innovative support of prevention and care and the maintenance of sustained HIV viral suppression during the coronavirus disease 2019 (COVID-19) pandemic. This notice applies to due dates on or after 7 **September 2021** and subsequent receipt dates through 7 **May 2024**. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice:

- [PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-195](#) - NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)

[NOT-MH-21-270](#) Notice of Information: NIMH High-Priority Areas for Research on Women's Mental Health during the Perinatal Period The purpose of this notice is to outline high priority areas of research related to women's mental health during the perinatal period. NIMH is interested in receiving applications that will provide new knowledge in perinatal mental disorders and that will test strategies for translating this knowledge into improved diagnostics, therapies, and services to improve women's mental health during the perinatal period. This Notice of Information applies broadly to most but not all Funding Opportunity Announcements (FOAs) that are aligned with NIMH research priorities.

[NOT-AA-21-029](#) Notice of Special Interest: Genetics of Alcohol Sensitivity and Tolerance. The purpose of this notice of special interest (NOSI) is to provide enhanced understanding of genetic, genomic, and epigenetic factors contributing to biological processes for individual variation in sensitivity, the development of tolerance, and progression to AUD. NIAAA is interested in projects that will develop innovative strategies integrating both experimental and bioinformatics approaches to establish causality for candidate genes from GWAS and linkage studies and to provide insights into genetic mechanisms of alcohol sensitivity and the development of tolerance through investigation of genomic, epigenetic, or transcriptional variation, and gene network and pathway analyses. Applicants are encouraged to consider model systems in which these complex relationships can be better studied under defined genetic backgrounds and well-controlled environmental conditions. This notice applies to due dates on or after 5 **October 2021** and subsequent receipt dates through 8 **May 2024**. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice. Submit applications for this initiative using one of the following funding opportunity announcements

- [PAR-21-250](#) - Mechanisms of Alcohol Tolerance (R21/R33 - Clinical Trial Optional)
- [PA-19-055](#) - NIH Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-19-056](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-19-091](#) - NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

[NOT-AI-21-054](#) Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV. The purpose of this Notice of Special Interest (NOSI) is to promote and support innovative methods in Big Data Science (BDS) to identify unappreciated biomedical, behavioral, social patterns and other social determinants that shed light on HIV acquisition, transmission, the development of comorbidities, and long-term viral control as in the HIV treatment continuum. BDS approaches can bring together data to evaluate the complex interplay between individual, contextual, and structural factors influencing the epidemiology of risk and care. Further, because this field can reveal unexpected associations through analysis of diverse data, BDS approaches may reveal events that are unseen or transient in traditional analysis of datasets. Discovery of these events will considerably advance research on HIV networks of transmission and the care continuum. This NOSI will support the establishment of BDS standards, bioinformatics data tools, machine-learning algorithms, mathematical modeling, advanced epidemiology and statistical analytic methods, and consideration and application of privacy and ethical issues in the use of public and personal data in the context of HIV research. The areas below will NOT be supported through this NOSI:

- Establishment of new cohorts requiring primary data collection or generation
- Clinical trials requiring an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application or assessing the safety of the intervention
- Clinical trial planning activities for protocol development.

This notice applies to due dates on or after **7 September 2021** and subsequent receipt dates through **7 May 2024**. Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

- [PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

[NOT-CA-21-085](#) Notice of Special Interest (NOSI): New Information Technology-Enabled Care Delivery Models to Improve Depression Care in Cancer. This Notice of Special Interest (NOSI) highlights interest of the National Cancer Institute (NCI)'s Division of Cancer Control and Population Sciences in receiving investigator-initiated applications for conducting research on the design and implementation of new information technology (IT)-enabled care delivery models to improve depression-related care in cancer. This Notice applies to due dates on or after **5 October 2021** and subsequent receipt dates through **8 March 2024**. Submit applications for this initiative using one of the following funding opportunity announcements

- [PAR-21-035](#): Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
- [PAR-19-274](#): Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
- [PAR-19-275](#): Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
- [PAR-19-352](#): Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Healthcare Utilization (R01 Clinical Trial Optional)
- [PAR-19-355](#): Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Healthcare Utilization (R21 Clinical Trial Optional)
- [PAR-21-190](#): Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
- [PA-20-185](#): NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

[NOT-DA-21-030](#) Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience. This Notice of Special Interest [NOSI] is to support computational HIV/AIDS research as it relates to NIDA's mission through collaborative research between investigators with experimental expertise related to HIV/AIDS and those with computational proficiency, including scientists from statistics, physics, mathematics, engineering, and computer science. The NOSI will support meritorious and innovative research built on well-established computational strategies (theory, models, and methods) to investigate HIV-related neurocognitive deficits and neuropathogenesis in the context of substance use or substance use disorder (SUD). Investigators are expected to have complementary and integrated expertise in their field(s), but an ongoing collaboration or record of co-authorship is not required. This notice applies to due dates on or after **5 October 2021** and subsequent receipt dates through **8 January 2025**. Submit applications for this initiative using one of the following funding opportunity announcements

- [PA-20-185](#)- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#)- Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#)- Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-194](#)- NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-195](#)- NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

- [PA-20-196](#) - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required) [PA-18-916](#) - AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)

[NOT-HD-21-027](#) Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition The purpose of this Notice of Special Interest (NOSI) is to encourage applications in high-priority research areas related to pediatric health care transition for youth with chronic physical/medical conditions or intellectual/developmental disabilities. Research applications that will advance our understanding of promising practices designed to facilitate successful health care transitions (HCT) from pediatric to adult care settings as well as barriers and facilitators to such transition are encouraged. The ultimate goal is to improve care quality and patient and family outcomes during and after HCT. This notice applies to due dates on or after 5 June 2021 and subsequent receipt dates through 8 January 2024. Submit applications for this initiative using one of the following funding opportunity announcements

- [PA-20-183](#) - Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-194](#) - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-195](#) - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PAR-21-035](#) - Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
- [PAR-21-190](#) - Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-250](#)

Type: R21/R33

Application Due Date: 16 October 2021, 16 February 2022, 16 June 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial optional, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase.

Budget: For the R21 phase, the combined budget for direct costs during the two-year project period may not exceed \$275,000 with no more than \$200,000 requested in a single year. For the R33 phase, the direct costs should not exceed \$500,000 per year. The project period is limited to 2 years for the R21 phase and up to 3 years for the R33 phase. The total project period may not exceed 5 years.

2. Data Enhancements and Analyses to Clarify the Relationship between Education and Cognitive Function (including AD/ADRD) (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-22-025](#)

Type: R01

Application Due Date: 20 October 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications that propose to add enhanced measures of educational experiences, cognitive function, or both to existing studies and/or to conduct analyses that incorporate these measures to clarify the relationship between education, cognition, and risk of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD), including the role of education in social disparities in AD/ADRD outcomes.

Budget: NIA intends to commit \$3 million in FY 2022 to fund up to two awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

3. Program on the Origins of Gastroesophageal Cancers (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-21-026](#)

Type: R01

Application Due Date: 8 October 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The National Cancer Institute (NCI) is publishing this Funding Opportunity Announcement (FOA) to request applications for the Program on the Origins of Gastroesophageal Cancers (R01). This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular level. The program will address the complex mechanisms and effectors that direct the proliferation and expansion of tumor-initiating cells and their progeny to initiate these cancers. The focus of the FOA is on gastric and gastroesophageal junction adenocarcinomas. The program is envisioned to provide unprecedented opportunities to outline the earliest cellular changes in transformation that precede any histological manifestations or neoplasia. This new program will be composed of up to six large R01 research grants (to be supported by this FOA) and one Coordinating Center grant (to be supported by the companion FOA, [RFA-CA-21-027](#)).

Budget: NCI intends to fund up to 6 awards, corresponding to a total funding of \$5.8 million in fiscal year 2022. Future years amount will depend on annual appropriations. Application budget is limited to \$600,000 in direct costs per year. The maximum project period is 5 years.

4. Elucidating the Effects of ART on Neuronal Function in the Context of SUD and HIV (R01 - Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-22-003](#)

Type: R01

Application Due Date: 2 February 2022 Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The National Institute on Drug Abuse [NIDA] seeks research applications to identify the effects of anti-retroviral therapy (ART) used for the treatment of HIV/AIDS on neuronal and glial structure and function, particularly when occurring in a background of chronic exposure to addictive substances including opioids, cocaine and other stimulants, cannabinoids, and nicotine. The overall goal of this funding opportunity is to determine the contributions of ART in the neurological and neurocognitive deficits that are linked to HIV-Associated Neurocognitive Disorders [HAND] in people living with HIV (PLWH) and substance use disorders (SUD).

Budget: NIDA intends to commit \$3,000,000 in FY 2022 to fund 8 - 10 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

5. Large Scale Mapping and/or Molecular Profiling of Ensembles and/or Cell-Types Mediating Opioid Action in the Rodent Brain (R01 - Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-22-011](#)

Type: R01

Application Due Date: 15 October 2021 Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This funding opportunity announcement aims to support research that employs innovative scalable technologies to identify, map, and profile cellular ensembles and/or cell-types that produce and/or respond to opioids or that are engaged during different stages of opioid use (acute, chronic, withdrawal, abstinence, relapse). Emphasis is on single-cell resolution approaches that enable multimodal high-throughput functional mapping, anatomical characterization and molecular profiling of cell assemblies identified as targets of, or as primary sources of opioids in the brain.

Budget: NIDA intends to commit \$2M in FY2022 to fund 1-3 awards. Applications may not request more than \$700,000 direct costs for any one year. The maximum project period is 5 years.

6. National Institute on Deafness and Other Communication Disorders (NIDCD) Research Grants for Translating Basic Research into Clinical Tools (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DC-22-001](#)

Type: R01

Application Due Date: 20 October 2021, 20 June 2022, 22 February 2023, 18 October 2023. 20 June 2024 Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) is intended to provide an avenue for basic scientists, clinicians and clinical scientists to jointly initiate and conduct translational research projects which translate basic research findings into clinical tools for better human health. The scope of this FOA includes a range of activities to encourage translation of basic research findings which will impact the diagnosis, treatment and prevention of communication disorders. Connection to the clinical condition must be clearly established and the outcomes of the grant must have practical clinical impact.

Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NIDCD anticipates funding an estimated 2-3 awards in fiscal year 2022 for a total of \$1,500,000. Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request \$500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide. The scope of the proposed project should determine the project period. The maximum period is 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizel*
e: lizelk@sun.ac.za | t: +27 21 808 2105